NEULANDLABNeuland Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on NEULANDLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 136.4% YoY
- • Profit growth: 664.4% YoY
- • ROE: 19.4%
- • RSI: 59
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • Revenue growth: 136.4% YoY
- • Profit growth: 664.4% YoY
- • ROE: 19.4%
- • RSI: 59
Bear case
- • Valuation vs sector: P/E 82.9 vs sector 40.5
- • Dividend yield: 0.17%
- • MACD: bearish
- • Volume: 1.0x 20-day average
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Valuation vs sector: P/E 82.9 vs sector 40.5
- • Dividend yield: 0.17%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹723.50). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.